ID
11866
Description
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Keywords
Versions (5)
- 8/13/15 8/13/15 - Martin Dugas
- 5/23/16 5/23/16 -
- 5/28/16 5/28/16 -
- 5/28/16 5/28/16 -
- 6/6/16 6/6/16 -
Uploaded on
August 13, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Trial Medication Multiple Sclerosis ALAIN01 NCT02419378
Trial Medication Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE
Description
Trial Medication RQG
Description
Trial Medication: Date of Administration
Data type
date
Description
Trial Medication: Date of Administration Status
Data type
text
Description
Trial Medication: Dose administered
Data type
float
Measurement units
- mg
Alias
- UMLS CUI [1]
- C3174092
Description
Trial Medication: Batch No
Data type
text
Alias
- UMLS CUI [1]
- C3641829
Description
Trial Medication: Expiry Date
Data type
date
Description
Trial Medication: Expiry Date Status
Data type
text
Description
Trial Medication: Reason if less than 12 mg
Data type
text
Similar models
Trial Medication Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE